Sarepta Therapeutics (NASDAQ:SRPT) Given "Market Perform" Rating at William Blair

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "market perform" rating restated by equities research analysts at William Blair in a research report issued on Friday,Benzinga reports.

Other equities analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft dropped their target price on Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating for the company in a research report on Tuesday. BMO Capital Markets cut Sarepta Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $120.00 to $70.00 in a report on Monday. Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $60.00 to $30.00 and set an "outperform" rating for the company in a research note on Tuesday. Barclays lowered their price objective on Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Royal Bank Of Canada lowered their price objective on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research report on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $70.76.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $20.77 on Friday. Sarepta Therapeutics has a 52-week low of $18.30 and a 52-week high of $173.25. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -7.72 and a beta of 0.61. The company's fifty day moving average is $43.71 and its two-hundred day moving average is $83.62. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company's quarterly revenue was up 80.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 EPS. Equities research analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company's stock valued at $1,104,701,000 after buying an additional 117,904 shares during the period. Capital International Investors lifted its position in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 11.1% in the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company's stock worth $348,368,000 after buying an additional 285,100 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after buying an additional 577,848 shares during the period. Finally, T. Rowe Price Investment Management Inc. grew its position in shares of Sarepta Therapeutics by 2.1% during the first quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock valued at $127,512,000 after purchasing an additional 41,408 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.